We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bio Path Holdings Inc | NASDAQ:BPTH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.16 | -5.80% | 2.60 | 2.60 | 2.79 | 2.7985 | 2.57 | 2.76 | 52,201 | 23:52:51 |
A live webcast of the presentation can be accessed under “Events” in the Media section of the Company’s website at www.biopathholdings.com.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’ConnorStern Investor Relations 212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
1 Year Bio Path Chart |
1 Month Bio Path Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions